Dose Escalation Study of BI 2536 BS in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit
Primary: Maximum tolerated dose (MTD) Secondary: Determination of the pharmacokinetic profile of BI 2536. Assessment of safety and efficacy.
Neoplasms
DRUG: BI 2536
Determination of the maximum tolerated dose (MTD) by occurrence of dose limiting toxicities (DLT), up to 3 weeks
Number of patients with drug-related adverse events, according to common terminology criteria for adverse events (CTCAE) 3.0, up to 24 days after last drug administration|Number of patients with abnormal laboratory findings, up to 24 days after last drug administration|Change in Eastern Cooperative Oncology Group (ECOG) performance score, baseline, up to 24 days after last drug administration|Number of patients with clinically significant changes in vital signs, up to 24 days after last drug administration|Number of patients with objective tumor response, up to 24 days after last drug administration|Cmax (maximum concentration of the analyte in plasma), up to 264 hours after drug administration|tmax (time from dosing to maximum concentration), up to 264 hours after drug administration|AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity), up to 264 hours after drug administration|%AUC0-tz (the percentage of the AUC0-∞ that is obtained by extrapolation), up to 264 hours after drug administration|λz (terminal rate constant in plasma), up to 264 hours after drug administration|t1/2 (terminal half-life of the analyte in plasma), up to 264 hours after drug administration|MRT (mean residence time of the analyte in the body after intravenous administration), up to 264 hours after drug administration|CL (total clearance of the analyte in the plasma after intravascular administration), up to 264 hours after drug administration|Vz (apparent volume of distribution during the terminal phase λz following an intravascular dose), up to 264 hours after drug administration|Vss (apparent volume of distribution at steady state following intravascular administration), up to 264 hours after drug administration
Primary: Maximum tolerated dose (MTD) Secondary: Determination of the pharmacokinetic profile of BI 2536. Assessment of safety and efficacy.